MX2016000386A - Proceso para la preparacion de un intermediario de pirimidina. - Google Patents
Proceso para la preparacion de un intermediario de pirimidina.Info
- Publication number
- MX2016000386A MX2016000386A MX2016000386A MX2016000386A MX2016000386A MX 2016000386 A MX2016000386 A MX 2016000386A MX 2016000386 A MX2016000386 A MX 2016000386A MX 2016000386 A MX2016000386 A MX 2016000386A MX 2016000386 A MX2016000386 A MX 2016000386A
- Authority
- MX
- Mexico
- Prior art keywords
- preparing
- macitentan
- bromophenyl
- pyrimidinyl
- oxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Detergent Compositions (AREA)
- Magnetic Heads (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Manufacturing Cores, Coils, And Magnets (AREA)
- Extraction Or Liquid Replacement (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
La invención se refiere a un proceso para la preparación de un intermediario de pirimidina es decir, el compuesto de la fórmula I-2 o una de sus sales. Dicho compuesto de la fórmula 1-2 o su sal puede ser usado para la preparación de macitentan. Macitentan (denominaciones químicas: N-[5-(4-bromofenil)-6-[2-[(5-bromo-2-pir imidinil)oxi]etoxi]-4-pirimidinil]-N'-propilsulfamida o N-[5-(4-bromofenil)-6-{2-[(5-bromopirimidin-2-il)oxi]etoxi}pirimi din-4-il]-N'-propilsulfúrico diamida) es un antagonista del receptor de endotelina que ha sido notablemente aprobado por la Administración de Drogas y Medicamentos de los Estados Unidos y la Comisión Europea para el tratamiento de la hipertensión arterial pulmonar. Se divulgó por primera vez en la Solicitud Internacional WO 02/053557. La última etapa de una de las posibles vías de preparación que se describen en la Solicitud Internacional WO 02/053557, denominada "Posibilidad A" y "Posibilidad B", puede resumirse como se muestra en el Esquema A1 a continuación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13176374 | 2013-07-12 | ||
| PCT/EP2014/064904 WO2015004265A1 (en) | 2013-07-12 | 2014-07-11 | Process for preparing a pyrimidine intermediate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016000386A true MX2016000386A (es) | 2016-04-29 |
| MX360768B MX360768B (es) | 2018-11-15 |
Family
ID=48790244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016000386A MX360768B (es) | 2013-07-12 | 2014-07-11 | Proceso para la preparacion de un intermediario de pirimidina. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9556125B2 (es) |
| EP (1) | EP3019479B1 (es) |
| JP (1) | JP6375374B2 (es) |
| KR (1) | KR102305298B1 (es) |
| CN (1) | CN105636940B (es) |
| AR (1) | AR096865A1 (es) |
| CA (1) | CA2915736C (es) |
| DK (1) | DK3019479T3 (es) |
| ES (1) | ES2636937T3 (es) |
| HR (1) | HRP20171166T1 (es) |
| HU (1) | HUE034071T2 (es) |
| IL (1) | IL243477B (es) |
| MX (1) | MX360768B (es) |
| PL (1) | PL3019479T3 (es) |
| PT (1) | PT3019479T (es) |
| TW (1) | TWI643848B (es) |
| WO (1) | WO2015004265A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA201605808B (en) | 2015-08-26 | 2017-08-30 | Cipla Ltd | Process for preparing an endothelin receptor antagonist |
| CN105461638A (zh) * | 2015-12-10 | 2016-04-06 | 合肥久诺医药科技有限公司 | 一种马西替坦晶型及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0116237B8 (pt) | 2000-12-18 | 2021-05-25 | Actelion Pharmaceuticals Ltd | "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina". |
| CN103724281A (zh) * | 2013-12-03 | 2014-04-16 | 镇江圣安医药有限公司 | N-[5-（4-溴苯基）-6-[2-[（5-溴-2-嘧啶基）氧基]乙氧基]-4-嘧啶基]-n′-丙基磺酰胺的新型衍生物及其应用 |
| CN103819411A (zh) * | 2014-03-14 | 2014-05-28 | 成都克莱蒙医药科技有限公司 | 一种马西替坦中间体新的制备方法 |
-
2014
- 2014-07-10 AR ARP140102549A patent/AR096865A1/es active IP Right Grant
- 2014-07-11 PT PT147372726T patent/PT3019479T/pt unknown
- 2014-07-11 ES ES14737272.6T patent/ES2636937T3/es active Active
- 2014-07-11 HU HUE14737272A patent/HUE034071T2/en unknown
- 2014-07-11 DK DK14737272.6T patent/DK3019479T3/en active
- 2014-07-11 PL PL14737272T patent/PL3019479T3/pl unknown
- 2014-07-11 EP EP14737272.6A patent/EP3019479B1/en active Active
- 2014-07-11 CN CN201480039832.2A patent/CN105636940B/zh active Active
- 2014-07-11 JP JP2016524837A patent/JP6375374B2/ja active Active
- 2014-07-11 US US14/904,657 patent/US9556125B2/en active Active
- 2014-07-11 CA CA2915736A patent/CA2915736C/en active Active
- 2014-07-11 WO PCT/EP2014/064904 patent/WO2015004265A1/en active Application Filing
- 2014-07-11 KR KR1020167003201A patent/KR102305298B1/ko active IP Right Grant
- 2014-07-11 TW TW103124052A patent/TWI643848B/zh not_active IP Right Cessation
- 2014-07-11 MX MX2016000386A patent/MX360768B/es active IP Right Grant
-
2016
- 2016-01-06 IL IL243477A patent/IL243477B/en active IP Right Grant
-
2017
- 2017-07-31 HR HRP20171166TT patent/HRP20171166T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3019479B1 (en) | 2017-05-10 |
| JP6375374B2 (ja) | 2018-08-15 |
| KR20160030972A (ko) | 2016-03-21 |
| EP3019479A1 (en) | 2016-05-18 |
| PT3019479T (pt) | 2017-08-11 |
| IL243477B (en) | 2018-06-28 |
| HRP20171166T1 (hr) | 2017-10-06 |
| WO2015004265A1 (en) | 2015-01-15 |
| CN105636940A (zh) | 2016-06-01 |
| CN105636940B (zh) | 2018-02-27 |
| MX360768B (es) | 2018-11-15 |
| US9556125B2 (en) | 2017-01-31 |
| PL3019479T3 (pl) | 2017-10-31 |
| TW201536759A (zh) | 2015-10-01 |
| HUE034071T2 (en) | 2018-01-29 |
| ES2636937T3 (es) | 2017-10-10 |
| US20160145215A1 (en) | 2016-05-26 |
| CA2915736A1 (en) | 2015-01-15 |
| CA2915736C (en) | 2021-07-27 |
| DK3019479T3 (en) | 2017-07-17 |
| AR096865A1 (es) | 2016-02-03 |
| TWI643848B (zh) | 2018-12-11 |
| JP2016525094A (ja) | 2016-08-22 |
| KR102305298B1 (ko) | 2021-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500166A1 (en) | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors | |
| GEP201706774B (en) | Heterocyclyl compounds | |
| JP2016514717A5 (es) | ||
| EA201790228A1 (ru) | Композиции и способы получения пиримидиновых и пиридиновых соединений с btk ингибирующей активностью | |
| PH12016500531A1 (en) | Compound inhibiting activities of btk and/or jak3 kinases | |
| MX2022000826A (es) | Composiciones de forma de dosificacion que comprenden un inhibidor de tirosina cinasa de bruton. | |
| EA201370166A1 (ru) | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы | |
| EA202091324A1 (ru) | Комбинация 4-пиримидинсульфамидного производного с ингибитором sglt-2 для лечения заболеваний, связанных с эндотелином | |
| MY199042A (en) | Aminopyrimidine compound, preparation method therefor and use thereof | |
| EA201591195A1 (ru) | Новые хинолоновые производные | |
| TN2013000216A1 (en) | Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine | |
| EA201101186A1 (ru) | Конденсированные пиримидины | |
| MX2009013272A (es) | Formas amorfas estabilzadas de mesilato de imatinib. | |
| CY1124329T1 (el) | N-(6-((2r,3s)-3,4-δiyδpoξyboytan-2-yλoξy)-2-(4-φθοροβενζυλοθειο)πυριμιδιν-4-υλ)-3-μεθυλαζετιδιν-1-σουλφοναμιδιο ως ρυθμιστης του υποδοχεα χημειοκινων | |
| EA201992501A1 (ru) | Соль соединения производного аминопиридина, ее кристаллическая форма и способ получения | |
| RU2018131775A (ru) | 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета | |
| MX2017011330A (es) | Proceso quimico para preparar derivados de pirimidina y sus intermediarios. | |
| EP2584901A4 (en) | PROCESS FOR PREPARING THE INTERMEDIATE OF STRAIN AND STRAIN OF POLYMORPHS | |
| MX2016000386A (es) | Proceso para la preparacion de un intermediario de pirimidina. | |
| EA201390771A1 (ru) | Способ получения фармацевтических промежуточных соединений высокой чистоты | |
| MX2017008430A (es) | Métodos para preparar derivados de 2,4-diaminopirimidina bíclica fusionada. | |
| MX2021013300A (es) | Forma sólida de un compuesto de diaminopirimidina o un hidrato del mismo, método de preparación del mismo, y aplicación del mismo. | |
| HRP20100641T1 (hr) | Imidazolidinonilaminopirimidinski spojevi za liječenje raka | |
| EA201791354A2 (ru) | Препараты производных пиримидиндиона | |
| MX2013005960A (es) | Metodo para preparar sales de rosuvastatina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |